Novo Nordisk

Novo Nordisk A/S is a global healthcare company, which engages in the the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care, and Biopharm segments. The Diabetes and Obesity Care segment includes insulin, GLP-1 and related delivery systems, oral antidiabetic products (OAD), obesity, and other serious chronic diseases. The Biopharm segment focuses on rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1925 is headquartered in Bagsværd, Denmark.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care, and Rare Disease segments. The Diabetes and Obesity Care segment includes diabetes, obesity, cardiovascular, and emerging therapy areas. The Rare Disease segment refers to rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1923 is headquartered in Bagsværd, Denmark.

AbbVie

Vertex Pharmaceuticals

Santa Claus will soon be on his way delivering presents to kids around the world. But could the jolly gift-giver bring something for investors, too?

3 Fantastic Stocks That Could Enjoy a Santa Claus Rally

The U.S. Food and Drug Administration has approved Novo Nordisk's drug for the prevention or reduction of bleeding episodes in patients with a type of blood-related disorder called hemophilia A, the agency said on Friday.

US FDA approves Novo Nordisk's bleeding disorder drug

CagriSema, a drug that Novo Nordisk had hoped would become its next generation weight-loss aid, has failed to meet expectations in late-stage trials, sending shares of the pharmaceutical giant tumbling as much as 24% at one point in premarket trading on Friday morning.

Novo Nordisk stock price takes a tumble after the Wegovy maker's next-generation weight-loss drug underwhelms

U.S. stocks traded higher midway through trading, with the Nasdaq Composite jumping more than 300 points on Friday.

Nasdaq Jumps Over 300 Points, Novo Nordisk Shares Spike Higher

Novo Nordisk A/S NVO is seeing its stock spiral downwards, with shares plummeting 20% early Friday following the release of Phase 3 trial data.

Novo Nordisk Stock Plummets: Bearish Signals Dominate After Drug Trial Miss

Novo Nordisk shareholders were seeking on Friday to find out why such a high number of patients in the late-stage trial of its next-generation obesity drug candidate CagriSema did not reach the highest dose strength of the medicine.

Novo Nordisk's dosing in CagriSema obesity drug trial puzzles investors

Novo Nordisk A/S (CPH: NOVO-B) is being punished this morning after posting a disappointing update related to CagriSema. The pharmaceutical behemoth said its experimental weight-loss treatment helped patients lower their weight by 22.7% in a late-stage trial – lower than 25% it had originally expected.

Novo Nordisk stock just tanked 25%: here's what happened

Bad news for Novo Nordisk (NVO -17.77%) Friday was good news for Eli Lilly (LLY 4.88%) and Viking Therapeutics (VKTX 5.86%), its two main rivals in the field of weight loss drugs. This morning, Novo reported headline results from its phase 3 trial of a new weight loss drug, CagriSema, and while objectively not bad, the results were less great than Novo was shooting for.

Why Novo Nordisk Stock Got Destroyed Today, but Eli Lilly and Viking Stocks Are Up

Investors and analysts had eagerly awaited this data as a test of Novo's case that it has a strong pipeline of drugs to follow Wegovy in the fiercely competitive anti-obesity market.

Novo Nordisk shares plummet after weight-loss drug's disappointing trial results

The Zacks Focus List offers investors a way to easily find top-rated stocks and build a winning investment portfolio. Here's why you should take advantage.

Earnings Growth & Price Strength Make Novo Nordisk (NVO) a Stock to Watch

Novo Nordisk A/S (NYSE:NVO) stock is down 18.9% to trade at $82.25 at last check, after the pharmaceutical company's  weight loss drug  CagriSema missed expectations of a late-stage study.

Novo Nordisk Stock Eyes Worst Day, Week on Record

Shares of Novo Nordisk A/S are down after underwhelming REDEFINE-1 trial results. The results were positive, but underperformed company and market expectations (including my own). The trial's flexible dosing protocol led to fewer patients reaching the highest dose, impacting the overall efficacy results.

Novo Nordisk: CagriSema Underwhelms In REDEFINE-1 Trial

As I'm writing these lines, Novo Nordisk A/S stock is down about 16% on the pre-market session after the news came out that CagriSema delivered disappointing trial results. I think this selloff is a rare buying opportunity to buy NVO stock at about fair stock price, judging by the long-term average valuation ratios. The business experienced 22.7% YoY revenue growth in US dollars during Q3 FY2024 and managed to expand its EBIT margin to over 47% (+95 bps QoQ and +161 bps YoY).

Novo Nordisk Stock: A Rare Buying Opportunity

Novo Nordisk (NYSE:NVO) shares plunged more than 20% before Friday's opening bell after the drugmaker reported results from a late-stage trial of its weight loss drug CagriSema that fell short of expectations. The company reported that patients in the trial achieved weight loss of 22.7% after 68 weeks, below the 25% it had previously guided.

Novo Nordisk shares drop after weight loss drug trial disappoints

Novo Nordisk's (NVO) U.S.-listed shares sank over 19% in premarket trading Friday after releasing trial results for its next generation of weight loss drug, meant to add to its current lineup of Ozempic and Wegovy.

Novo Nordisk Sinks on Disappointing Trial Results for Next Gen Weight Loss Drug

Novo Nordisk stock crashed Friday after the Danish giant reported its experimental obesity drug CagriSegma missed goals. Eli Lilly and Viking Therapeutics jumped The post Novo Nordisk Dives On CagriSegma Obesity Drug Trial.

Novo Nordisk Dives On CagriSegma Obesity Drug Trial. Eli Lilly, Viking Jump.

Novo Nordisk said on Friday it will begin a new trial of its experimental next-generation CagriSema drug in the first half of 2025 that it hopes will show greater weight-loss, after posting disappointing late-stage trial data.

Novo Nordisk to explore CagriSema weight-loss potential in new trial

Bagsværd, Denmark, 20 December 2024 – On 11 November 2024, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the "Safe Harbour Rules"). This programme is part of the overall share repurchase programme of up to DKK 20 billion to be executed during a 12-month period beginning 6 February 2024.

Novo Nordisk A/S - share repurchase programme

Novo Nordisk's stock dives as new weight loss drug disappoints in a late-stage trial, which gave a boost to Eli Lilly shares.

Novo Nordisk's new weight-loss drug works better, but not as well as expected

On Friday, Novo Nordisk A/S NVO stock plunged after the company released headline results from the REDEFINE 1 Phase 3 trial in the global REDEFINE program.

Novo Nordisk's Hybrid Weight Loss Drug Falls Short On Expectations, Stock Plunges

Shares of Danish pharmaceutical giant Novo Nordisk plummeted more than 22% on Friday after reporting results in a late-stage trial that missed expectations.

Novo Nordisk shares plunge 22% after CagriSema obesity drug trial results

Eli Lilly

The experimental obesity drug CagriSema disappointed investors.

Novo Nordisk Stock Crashes 22% After Disappoitning Obesity Drug Data. Eli Lilly Shares Soar.

Novo Nordisk said on Friday its experimental next-generation obesity drug CagriSema helped overweight patients cut their weight by 22.7% in a late-stage trial, below the 25% it had expected, sending its shares down sharply.

Novo Nordisk's next-gen obesity drug CagriSema achieves lower weight loss than expected

Bagsværd, Denmark, 20 December 2024 – Novo Nordisk today announced headline results from REDEFINE 1, a phase 3 trial in the global REDEFINE programme. REDEFINE 1 is a 68-week efficacy and safety trial investigating subcutaneous CagriSema (a fixed dose combination of cagrilintide 2.4 mg and semaglutide 2.4 mg) compared to the individual components cagrilintide 2.4 mg, semaglutide 2.4 mg and placebo, all administered once-weekly. The trial included 3,417 randomised people with obesity or overweight with one or more comorbidities and a mean baseline body weight of 106.9 kg.

Novo Nordisk A/S: CagriSema demonstrates superior weight loss in adults with obesity or overweight in the REDEFINE 1 trial

As Novo Nordisk and Eli Lilly expand sales of their popular diabetes and weight-loss drugs, cheaper copies of their patented remedies are winning approval from some regulators overseas, posing a threat to the pharma giants' prices and market share.

News for Novo Nordisk Stock (NVO)